卵巢肿瘤 | Medical guideline

首页 肿瘤学指南  卵巢肿瘤

卵巢肿瘤

按发表年份

Relapsed Ovarian Cancer - Diagnosis Using 18F-FDG PET/CT; 4

 2019年发布于 Rev Assoc Med Bras (1992) 65卷第4期 所属人体系统：生殖 | 卵巢肿瘤

 Brazilian Medical Association

Relapsed Ovarian Cancer Diagnosis Guideline
指南简介 原文链接
Bevacizumab with Carboplatin, Gemcitabine and Paclitaxel for Treating the First Recurrence of Platinum-sensitive Advanced Ovarian Cancer (Terminated Appraisal)

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

Ovarian Cancer treatment Bevacizumab carboplatin gemcitabine paclitaxel
指南简介 原文链接
ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

 2019年发布于 Int J Gynecol Cancer 29卷第_期 所属人体系统：生殖 | 卵巢肿瘤

 European Society for Medical Oncology European Society of Gynaecologic Oncology Ovarian Cancer Consensus Conference Working Group

Adjuvant Treatment Molecular Biology Ovarian Cancer Pathology Recurrent Disease Surgery
指南简介 原文链接
Diagnostik, Therapie Und Nachsorge Maligner Ovarialtumoren. S3-LL (Leitlinienprogramm Onkologie Von AWMF, DKG Und DKH)(English Title Translation: Diagnosis, Treatment and Aftercare of Malignant Tumors of the Ovary)

 2019年 所属人体系统：生殖 | 卵巢肿瘤

 Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften

Malignant Tumors of the Ovary Diagnostics Therapy Aftercare
指南简介 原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man

 2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 卵巢肿瘤

 FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique) Au CNGOF (Collège National Des Gynécologues Obstétriciens Français) À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).

Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert a Subjective Analysis Is Optimal. If Performed by a Non-expert Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert) a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian Fallopian Tube Or Primary Peritoneal Cancer It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2 Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency GFR <30mL/min) an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3 Grade C). by Analogy the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3 Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3 Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa

 2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 卵巢肿瘤

 FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancers (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete 6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended Or a Discussion with the Patient About Intraperitoneal Chemotherapy According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology

 2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 卵巢肿瘤

 FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancer (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介 原文链接
Rucaparib for Maintenance Treatment of Relapsed Platinum-sensitive Ovarian, Fallopian Tube Or Peritoneal Cancer

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

指南简介 原文链接
Olaparib for Maintenance Treatment of BRCA Mutation-positive Advanced Ovarian, Fallopian Tube Or Peritoneal Cancer after Response to First-line Platinum-based Chemotherapy

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

指南简介 原文链接
卵巢恶性肿瘤诊断与治疗指南(第四版)

 2018年发布于中国实用妇科与产科杂志 34卷第7期 所属人体系统：生殖 | 卵巢肿瘤

 中国抗癌协会妇科肿瘤专业委员会

卵巢肿瘤诊断治疗指南
指南简介 原文链接
聚乙二醇化脂质体阿霉素治疗卵巢癌的中国专家共识(2018年)

 2018年发布于现代妇产科进展 27卷第9期 所属人体系统：生殖 | 卵巢肿瘤

 中华医学会妇科肿瘤学分会

聚乙二醇化脂质体阿霉素卵巢癌专家共识
指南简介 原文链接
PARP抑制剂治疗复发性卵巢癌专家共识

 2018年发布于现代妇产科进展 27卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 无

PARP抑制剂卵巢癌专家共识
指南简介 原文链接
Surgery in Ovarian Cancer - Brazilian Society of Surgical Oncology Consensus

 2018年发布于 BJOG 125卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 Brazilian Society of Surgical Oncology

Brazilian Society of Surgical Oncology Consensus Epithelial Ovarian Cancer Surgery
指南简介 原文链接
Practice Guidelines for Management of Ovarian Cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

 2018年发布于 J Gynecol Oncol 29卷第4期 所属人体系统：生殖 | 卵巢肿瘤

 Korean Society of Gynecologic Oncology

Consensus Drug Therapy General Surgery Ovarian Neoplasms Practice Guideline
指南简介 原文链接
Niraparib for Maintenance Treatment of Relapsed, Platinum-sensitive Ovarian, Fallopian Tube and Peritoneal Cancer

 2018年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

指南简介 原文链接
Management of Epithelial Ovarian Cancer

 2018年 所属人体系统：生殖 | 卵巢肿瘤

 Scottish Intercollegiate Guidelines Network

Ovarian Cancer screening diagnosis treatment follow-up
指南简介 原文链接
Fertility Preservation, Contraception and Menopause Hormone Therapy in Women Treated for Rare Ovarian Tumors: Guidelines from the French National Network Dedicated to Rare Gynaecological Cancer

 2018年发布于 Eur J Cancer 所属人体系统：生殖 | 卵巢肿瘤

 A Panel of Experts from the French National Network Dedicated to Rare Gynaecological Cancers and Experts in Reproductive Medicine and Gynaecology

Assisted Reproductive Technology Borderline Ovarian Tumour Contraception Controlled Ovarian Stimulation Delphi Method Fertility Preservation Germ Cell Tumour Hormone Replacement Therapy Rare Ovarian Tumour Sex-cord Tumour
指南简介 原文链接
Recommendations for Biomarker Testing in Epithelial Ovarian Cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

 2018年发布于 Clin Transl Oncol 20卷第3期 所属人体系统：生殖 | 卵巢肿瘤

 The Spanish Society of Pathology and the Spanish Society of Medical Oncology

BRCA Diagnosis Mutations Prognosis Screening
指南简介 原文链接
The French Genetic and Cancer Consortium Guidelines for Multigene Panel Analysis in Hereditary Breast and Ovarian Cancer Predisposition

 2018年发布于 Bull Cancer 105卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 The French Genetic and Cancer Consortium

Breast Cancer Cancer De L’ovaire Cancer Du Sein Cancer Genetics Cancers Héréditaires Conseil Génétique Genetic Counseling Guidelines Mutigene Panels Ovarian Cancer Panel De Gènes Recommandations
指南简介 原文链接
No. 230-Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian Masses

 2018年发布于 J Obstet Gynaecol Can 40卷第3期 所属人体系统：生殖 | 卵巢肿瘤

 无

Pelvic Mass Oncology Ovarian Mass Surgical Management Ultrasound Evaluation
指南简介 原文链接

人体系统

 2019年 发布于 Rev Assoc Med Bras (1992) 65卷 第4期 所属人体系统： 生殖 | 卵巢肿瘤

 Brazilian Medical Association

 2019年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

 2019年 发布于 Int J Gynecol Cancer 29卷 第_期 所属人体系统： 生殖 | 卵巢肿瘤

 European Society for Medical Oncology European Society of Gynaecologic Oncology Ovarian Cancer Consensus Conference Working Group

 2019年 所属人体系统： 生殖 | 卵巢肿瘤

 Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften

 2019年 发布于 Gynecol Obstet Fertil Senol 47卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

 2019年 发布于 Eur J Obstet Gynecol Reprod Biol 236卷 第_期 所属人体系统： 生殖 | 卵巢肿瘤

 2019年 发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷 第6期 所属人体系统： 生殖 | 卵巢肿瘤

 2019年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

 2019年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

 2018年 发布于 中国实用妇科与产科杂志 34卷 第7期 所属人体系统： 生殖 | 卵巢肿瘤

 中国抗癌协会妇科肿瘤专业委员会

 2018年 发布于 现代妇产科进展 27卷 第9期 所属人体系统： 生殖 | 卵巢肿瘤

 中华医学会妇科肿瘤学分会

 2018年 发布于 现代妇产科进展 27卷 第10期 所属人体系统： 生殖 | 卵巢肿瘤

 无

 2018年 发布于 BJOG 125卷 第10期 所属人体系统： 生殖 | 卵巢肿瘤

 Brazilian Society of Surgical Oncology

 2018年 发布于 J Gynecol Oncol 29卷 第4期 所属人体系统： 生殖 | 卵巢肿瘤

 Korean Society of Gynecologic Oncology

 2018年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 卵巢肿瘤

 National Institute for Health and Care Excellence

 2018年 所属人体系统： 生殖 | 卵巢肿瘤

 Scottish Intercollegiate Guidelines Network

 2018年 发布于 Eur J Cancer 所属人体系统： 生殖 | 卵巢肿瘤

 A Panel of Experts from the French National Network Dedicated to Rare Gynaecological Cancers and Experts in Reproductive Medicine and Gynaecology

 2018年 发布于 Clin Transl Oncol 20卷 第3期 所属人体系统： 生殖 | 卵巢肿瘤

 The Spanish Society of Pathology and the Spanish Society of Medical Oncology

 2018年 发布于 Bull Cancer 105卷 第10期 所属人体系统： 生殖 | 卵巢肿瘤

 The French Genetic and Cancer Consortium

 2018年 发布于 J Obstet Gynaecol Can 40卷 第3期 所属人体系统： 生殖 | 卵巢肿瘤

 无

 2019年发布于 Rev Assoc Med Bras (1992) 65卷第4期 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 Int J Gynecol Cancer 29卷第_期 所属人体系统：生殖 | 卵巢肿瘤

 2019年 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于中国实用妇科与产科杂志 34卷第7期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于现代妇产科进展 27卷第9期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于现代妇产科进展 27卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 BJOG 125卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 J Gynecol Oncol 29卷第4期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 卵巢肿瘤

 2018年 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 Eur J Cancer 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 Clin Transl Oncol 20卷第3期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 Bull Cancer 105卷第10期 所属人体系统：生殖 | 卵巢肿瘤

 2018年发布于 J Obstet Gynaecol Can 40卷第3期 所属人体系统：生殖 | 卵巢肿瘤